-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Bright Minds Biosciences, Raises Price Target to $147

Benzinga·01/07/2026 11:54:33
Listen to the news
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $72 to $147.